C. diff Vaccine Advances to Phase III Trial

A vaccine for C. diff is now one step closer to reality. The potential vaccine, developed by Sanofi Pasteur, has performed well in two initial trials and has now moved on to a large Phase III trial.

During an earlier testing phase, researchers saw a significant increase in antibody production against C. diff toxins in volunteers between the ages of 40 and 75. Elderly recipients experienced particularly strong immune responses.

The vaccine is designed to work the same way as the tetanus or whooping cough vaccines, by stimulating the immune system to fight C. diff when it appears.

To learn more, click here.